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Abstract The aim of this study was to determine the
susceptibility of murine embryonic stem (mESCs) to
mouse hepatitis virus (MHV-A59) and mouse minute
virus (MMVp) and the effect of these viruses on
germline transmission (GLT) and the serological
statusofrecipientsandpups.Whenrecipientsreceived
10 blastocysts, each injected with 10
0 TCID50 MHV-
A59,threeoutofﬁverecipientsandfouroutof14pups
from three litters became seropositive. When blasto-
cysts were injectedwith 10
-5 TCID50 MMVp, all four
recipients and 14 pups from four litters remained
seronegative. The mESCs replicated MHV-A59 but
not MMVp, MHV-A59 being cytolytic for mESCs.
Exposure of mESCs to the viruses over four to ﬁve
passagesbutnotfor6 haffectedGLT.Recipientswere
seropositive for MHV-A59 but not for MMVp when
mESCs were cultured with the virus over four or ﬁve
passages.Thedata show that GLT is affected by virus-
contaminated mESCs.
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Introduction
Transfection of murine embryonic stem cells
(mESCs) with the desired gene constructs and
injection into blastocysts coupled with transfer to
suitable recipients is a standardized method for
producing transgenic mice (Gossler et al. 1986).
However, besides feeder cells and blastocysts,
mESCs can harbor murine pathogens (Okumura et al.
1996; Kyuwa et al. 1997) and their introduction into
a mouse colony can lead to spread of infections. Due
to the exchange of mESCs between laboratories
worldwide the risk of transmitting mouse infectious
agents may even be higher since mESCs are often not
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with viruses cannot be detected on the basis of cell
morphology.
Mouse hepatitis virus (MHV) and mouse minute
virus (MMV) have a size of 80–160 nm and 20 nm,
respectively, and are infectious agents that are relevant
for routine health monitoring of contemporary mouse
colonies (Nicklas et al. 2002). MHV belongs to the
coronavirus family of enveloped, positive-strand ribo-
nucleic acid (RNA) viruses and its replication occurs in
thecytoplasmofcells(Braytonet al.1981;Gosertetal.
2002). MMV is a non-enveloped, linear positive-strand
deoxyribonucleic acid (DNA) virus of the Parvoviridae
familyandreplicatesinthenucleusofmitoticallyactive
cells (Tattersall 1972;L i n s e re ta l .1979).
Although a survey of 46 mESC lines did not show
the presence of murine infectious agents (Nicklas and
Weiss 2000) two studies showed that murine mESCs
became infected with MHV-2 and MHV-A59 and
continued to grow in vitro showing neither cytopathic
effects nor overt signs of differentiation (Okumura
et al. 1996; Kyuwa 1997). Since these studies were
performed in vitro no information is available on
whether transferring blastocysts which have been
injected with virus-exposed mESCs to recipients
affects the germline efﬁciency of the mESCs and if
and how soon after embryo transfer the recipients and
pupsshowspeciﬁcantibodiestosuchviruses.Thisisof
relevance to laboratory animal science since germline
transmission (GLT) is a necessity for the production
and use of transgenic mice. Also, infected mice affect
the outcome of animal experiments (Fox et al. 1977;
Kyriazis et al. 1979; Dempsey et al. 1986; Barthold
1986; Lussier 1988).
In the present study, the objectives were to (1)
investigatethesusceptibilityofmESCstoinfectionwith
MHV-A59 and MMVp, (2) investigate the effect of
MHV-A59- and MMVp-exposed mESCs on GLT and
the reproductive performance of the recipients, and (3)
determine the serological status of recipients and pups
under routine working conditions at our mouse facility.
Materials and methods
Cells and viruses
Virus stocks of MHV-A59 (VR-764) and MMVp
(VR-1346) and their producer cell lines NCTC-1469
(CCL-9.1) and A9 (CCL-1.4), respectively, and L929
cells (CCL-1) were obtained from the American Type
Culture Collection (Manassas, VA, USA). NCTC-
1469 and A9 were used for propagation of MHV-A59
and MMVp, respectively, while L929 cells were used
for titration of both viruses. NCTC-1469, A9, and
L929 cell cultures were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented
with 4.5 g/l D-glucose/L-glutamine and 10% heat-
inactivated fetal calf serum (L929 in 5% fetal calf
serum). Propagation of virus stocks was performed in
75 cm
2 cell culture ﬂasks (NCTC-1469 in cell culture
ﬂasks from Corning Costar, Cambridge, Maryland,
USA; A9 and L929 in cell culture ﬂasks obtained
from Nunc, Roskilde, DK) at 37C using 5% CO2 in a
humidiﬁed atmosphere. Cultures of permissive cells
were infected with the appropriate virus for 1 h
followed by removal of the virus suspension and
replacing it with 10 ml cell culture medium. MHV-
A59- and MMVp-infected cells were frozen in their
culture ﬂasks after 20 h and 5 days, respectively.
They were subjected to three freeze-thaw cycles to
allow release of the virus. The contents of the ﬂasks
were centrifuged at 3,000g for 5 min to separate virus
from cell debris. The supernatant was passed through
a Minisart
 ﬁlter having a pore size of 0.20 lm
(Sartorius, Go ¨ttingen, Germany). For titration, L929
cells were seeded in 96-well plates at a concentration
of 2 9 10
4/well for MHV-A59 and 3 9 10
3/well for
MMVp and cultured overnight. After removal of the
culture medium, for each 10-fold dilution up to
10
-10, 12 wells were inoculated with 100 ll of the
virus. The cytopathic effect (CPE), observed as
syncytia and cytolysis for MHV-A59 and detachment
of cells for the MMVp infection, was determined on
the second and sixth day of culture, respectively. The
mean tissue culture infective dose (TCID50) for each
viral stock was calculated according to the Spear-
man–Kaerber method (Spearman 1908; Kaerber
1931). The MHV-A59 and MMVp stocks used in
this study had titers of 10
9 and 10
4 TCID50/ml,
respectively, and were stored at -80C until used.
Mice and husbandry
Outbred Crl:CD1(Icr)/Dcm (Dcm = Department of
Comparative Medicine) mice were bred in a full
barrier unit at our animal facilities. Breeding colonies
were kept in ﬁlter-topped Type II Makrolon
 cages at
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123a temperature of 20–24C, humidity of 50–60%, 20
air exchanges per hour and a 12/12-h light/dark cycle.
Wood shavings (Altromin, Lage, Germany) were
provided as bedding. Mice were fed a standardized
mouse diet (1314, Altromin) and provided drinking
water ad libitum.
Staff wore clean suits, disposable gloves, bonnets,
and face masks. Mice were transferred to new
individually ventilated cages (IVCs, VentiRacks
TM;
BioZone, Margate, UK) in class II laminar ﬂow
changing stations with disinfected forceps padded
with silicone tubing. All materials were autoclaved
before use.
Microbiological examination of mouse colonies
was performed every 6 weeks using male
Crl:CD1(Icr)/Dcm sentinels from the colony as
described (Mahabir et al. 2007). Brieﬂy, aliquots of
approximately 5 cm
3 of soiled bedding were taken
from each used cage on a rack. These aliquots were
mixed in a sterile box with an equivalent amount of
new sterile bedding, and the resultant mixture was
distributed to the sentinel cage of the same rack over
a period of 12 weeks. The serological examinations
were performed according to the annual standard
recommended by FELASA (Federation of Laboratory
Animal Science Associations) (Nicklas et al. 2002)
with the addition of Leptospira serogroups, ballum,
canicola, hebdomadis, and icterohaemorrhagiae,K
virus, Lactate dehydrogenase virus, Polyoma virus,
Mouse thymic virus, Hantaviruses (Kraft et al. 1994),
and since October 2006 murine norovirus. The mice
were found consistently negative for all of the above-
mentioned infectious agents including the ones
examined in this study.
Experimental and control mice were kept in IVCs
under positive pressure and the conditions stated
above. All animal manipulations were performed in a
class II laminar ﬂow biological safety cabinet
(Heraeus Instruments GmbH, Munich, Germany).
All animal studies were approved by the Helmholtz
Center Munich institutional animal care and use
committee and the Government of Upper Bavaria,
Germany (211-2531-8/02).
Experiment 1: blastocyst injection
with MHV-A59 and MMVp
About 6 to 8-week-old Crl:CD1(Icr)/Dcm females
were induced to ovulate by intraperitoneal injections
of 5 IU equine Chorionic Gonadotropin (eCG; Inter-
vet, Boxmeer, The Netherlands) followed 48 h later
by 5 IU human Chorionic Gonadotropin (hCG;
Intervet). They were mated immediately thereafter
with males of proven fertility. The presence of
vaginal plugs was determined the following morning
(d0.5). Mice were killed on d3.5, blastocysts were
ﬂushed from the uterine horns and collected in M2
medium (Quinn et al. 1982).
To determine if injection of MHV-A59 and
MMVp into blastocysts led to the birth of pups and
if mice seroconverted, approximately 1 nl of each
viral stock was injected into each blastocyst using a
micromanipulator (Leitz, Bensheim, Germany). A
total of 50 and 40 embryos was injected with MHV-
A59 and MMVp, respectively. For the control group,
20 embryos were injected with ESC medium. First,
control then viral-exposed blastocysts were injected.
Embryo transfer
A total of ﬁve blastocysts was transferred to each
uterus horn of d2.5 pseudopregnant recipients as
described (Nagy et al. 2003). First, control then viral-
exposed blastocysts were transferred. Recipients were
kept singly in IVCs. Pups were kept with their
mothers until weaning at 21 days postpartum and
then singly in IVCs.
Serological analysis
To determine if the recipients seroconverted and the
time of seroconversion, sera were prepared on days
14, 21, 28, 42, and 63 after embryo transfer. Sera
from progeny were prepared on days 42, 63, 84, and
112 after embryo transfer to determine if the progeny
were seropositive and if this antibody was maternal in
origin or if the progeny themselves became infected
with the virus. Blood was taken from mice receiving
control blastocysts then from mice receiving viral-
exposed blastocysts.
Sera were diluted 1 in 10 in phosphate-buffered
saline (PBS; Oxoid, Hants, UK) containing 0.05%
Tween 20 (R & L Slaughter, Essex, UK). They were
tested for speciﬁc antibodies (IgG whole molecule) to
MHV and MMV by use of an enzyme-linked
immunosorbent assay (ELISA) using control non-
viral-coated and viral-coated plates and negative and
positive serum. The MHV and MMV antigens were
Transgenic Res (2009) 18:45–57 47
123obtained from Churchill Applied Biotechnology Ltd.
(Cambridgeshire, UK). The optical density (OD) was
read at 492 nm with a Multiskan ELISA plate reader
(Thermo Life Sciences, Hampshire, UK). Sera were
equivocal low positive when the OD was 0.600–
0.799 and positive when OD values exceeded 0.799.
PCR analysis of organ samples from pups
For PCR analysis, three pups from each of the three
groupsinvestigatedinExperiment1werekilledwithin
3 days of birth and organs were collected. With regard
to the MHV PCR, total RNA from the liver and the
intestine was extracted using the QIAamp viral RNA
mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Precipitated RNA was
takenupin60 llRNase-freeAVEbufferwhichisalso
provided in the kit. The DNA present was removed by
RNase-free DNase (Qiagen). Immediately thereafter,
an RNase inhibitor (MBI Fermentas, St. Leon-Rot,
Germany) was added to the RT mixture at a concen-
tration of 10 U/ll. cDNA was synthesized using 12 ll
RNA and the Omniscript Reverse Transcriptase kit
(Qiagen). For PCR analysis, 1 lg( ll) cDNA was used
for ampliﬁcation. The primers used were those
designed by Taylor and Copley (1994): 50-CAG-
CCTGCCTCTACTGTAAAACC-30 (forward), 50-
GCCTCCAAAATTCTGATTGGGGC-30 (reverse),
yielding a 225-bp product. A double-distilled water
sample was used as a negative control in both the RT
and the PCR steps. PCR was performed in a total
volume of 20 ll using Taq DNA polymerase (Qiagen)
for 35 cycles in a thermocycler (Biometra, Biomediz-
inische Analytik GmbH, Go ¨ttingen, Germany).
Denaturation was performed at 94C for 4 min. Each
cycle consisted of 94C (60 s), 57C (60 s), and 72C
(45 s). The last cycle was followed by a 10-min
extension period at 72C.
DNA from the spleen and the kidney for the MMV
PCR was extracted using the QIAamp DNA mini kit
(Qiagen) according to the manufacturer’s instructions.
The primers used were those designed by Bootz et al.
(2003) as follows: 50-GAGCGCCATCTAGTGAG
C-30 (forward) and 50-ATTTGCCTGTGCTGGCT
G-30 (reverse), yielding a 483-bp product. A double-
distilled water sample served as a negative PCR
control. PCR was performed in a total volume of
20 ll using Taq DNA polymerase (Qiagen) for
40 cycles in a thermocycler (Biometra). Denaturation
wasperformedat94Cfor4 min.Eachcycleconsisted
of 94C (30 s), 55C (30 s) and 72C (30 s). The last
cycle was followed by a 7-min extension period at
72C.
PCR products (10 ll) from both virus groups and
the controls were mixed with 2 ll loading buffer
(MBI Fermentas), electrophoresed on a 1.5% agarose
gel, stained with ethidium bromide and visualized
under UV light.
Experiment 2: blastocyst injection
with viral-exposed mESCs
Culture of mESCs with MHV-A59 and MMVp
The mESC line with a 129/SvPas genetic background
was provided at passage 13 (P13) by W. Wurst,
Helmholtz Center Munich, Neuherberg, Germany
and showed GLT. Previous to their use in the present
study, mESCs were cultured on mitomycin C-inac-
tivated (1 mg/ml) murine embryonic feeder cells and
passaged every 2 days. Both mESCs and feeder cells
were free of mycoplasmas, pathogens listed in the
FELASA recommendations and murine norovirus.
Culture of the mESCs was performed in DMEM high
glucose, supplemented with 15% fetal calf serum, 1%
sodium pyruvate, 0.1 mM b-mercaptoethanol, 2 mM
glutamine, and 1,000 IU/ml LIF (Chemicon Interna-
tional Ltd, Hofheim, Germany).
A total of 1.134 9 10
6 mESCs in the 13th passage
(P13) was seeded at a density of 2 9 10
4 cells/cm
2 in
0.1% gelatin-coated 10-cm Petri dishes without
feeder cells and cultured for ﬁve passages
(P13 ? 5). At each of the ﬁve passages, trypsinized
cells were allowed to sediment for approximately
15–30 minintubesandmESCsforfurtherculturewere
taken from the top of the column thereby removing
feeder cells, which settled to the bottom of the tubes.
At P13 ? 5, the mESCs were then exposed to 10
4
or 10
-1 TCID50 MHV-A59 or 10
-1 TCID50 MMVp/
cell. After 6 h exposure to the virus, the inoculum was
removed and replaced with ESC culture medium.
Control mESCs were not exposed to the viruses. For
continued culture over four (P13 ? 5 ? 4, MHV-
A59) or ﬁve passages (P13 ? 5 ? 5, MMVp) in
0.1% gelatin-coated 10-cm Petri dishes without
feeder cells, mESCs inoculated with 10
-1 TCID50
virus/cell were passaged every 2 days. mESCs
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4 TCID50 MHV-A59/cell for 6 h were
used for blastocyst injection.
At each passage, cells were washed twice with PBS
(Gibco, Invitrogen
TM, Auckland, New Zealand), once
with trypsin/EDTA (Biochrom AG, Berlin, Germany)
and then trypsinized. The number of mESCs found in
the trypsinizedcellsuspensionswas determinedby the
use of a hemocytometer (Hycor Biomedical Inc.,
Kassel,Germany).Thetrypsinizedcellsuspensionsfor
further culture from each dish were pooled according
to the experimental group. The cell-free supernatants
were stored at -80C until titrated. The viability, the
viral status, and the pluripotency status of the trypsin-
ized mESCs from two replications was determined at
P13 ? 5 ? 1 by ﬂow cytometry as described below.
For determination of growth, blastocyst injection and
titration, further two replications each were performed
on two different days (cultures 1 and 2).
Antibodies and ﬂow cytometry
Anti-POU5F1 (formerly known as Oct-4) monoclonal
antibodies (clone 9E3, Chemicon, Chandlers Ford,
UK) were labeled with Cy5 monoreactive dye
(Amersham, Freiburg, Germany) as recommended
by the manufacturer. Anti-MHV-A59 and anti-
MMVp sera were collected from seropositive mice
at our facility. The immunoglobulin G (IgG) fraction
was puriﬁed using Prot-G Fast Flow chromatography
(Amersham) and labeled with ﬂuorescein isothiocy-
anate (FITC).
All cells were covalently stained with ethidium
monoazide (EMA; Molecular Probes, Karlsruhe,
Germany) in order to discriminate dead cells. They
were ﬁxed with 1% paraformaldehyde (PFA; Sigma,
Deisenhofen, Germany), permeabilized using 0.2%
saponin (Sigma) and labeled with the above-
described antibodies. The cells were processed with
a LSRII ﬂow cytometer (Becton Dickinson, Heidel-
berg, Germany) or a CyAn ﬂow cytometer (Daco-
Cytomation, Hamburg, Germany). The data were
analyzed using the FloJo software (Tree Star, Ash-
land, USA).
Virological examination of the cell culture
supernatants
The cell-free supernatants from the respective pas-
sages of the cultures with 10
-1 TCID50 MHV-A59 or
10
-1 TCID50 MMVp/cell were titrated as described
above for the viral stocks. The viral titers were
calculated using the Spearman–Kaerber method
(Spearman 1908; Kaerber 1931).
Blastocyst injection with viral-exposed mESCs
and embryo transfer
After 6 h exposure to the viruses or after four (MHV-
A59) or ﬁve (MMVp) passages, 15–20 mESCs were
injected into each blastocyst. Control blastocysts
received non-viral-exposed mESCs. Blastocyst injec-
tions, embryo transfers to d2.5 pseudopregnant
recipients and blood sampling were carried out with
controls ﬁrst. The serological status of recipients and
pups was determined as described for Experiment 1.
Germline transmission
To determine if the mESCs contributed to the
germline, chimeras obtained were mated with
C57BL/6 mice. The litter size, color, and gender of
mice were recorded. Progeny were either agouti with
a light-colored belly (GLT, originating from the 129
Sv/J strain) or black in color (wild type, originating
from the C57BL/6 strain).
Statistical analysis
Experimental groups were compared by Fisher’s
exact test. For the average number of cells found per
replicate after culture of virus-exposed and control
mESCs over passages, a Duncan’s multiple range test
was carried out. This test controlled the Type I
comparison wise error rate and allowed a ranking of
the cell numbers by passage number and treatment.
The global level of signiﬁcance was chosen to be
0.05. All statistical analyzes were performed using
SAS (SAS/STAT User’s Guide, Version 9.1. Cary,
NC; SAS Institute Inc., 2003).
Results
Experiment 1: injection of blastocysts with viral
suspensions and embryo transfer
In a ﬁrst step, blastocysts were microinjected with the
viral stocks to determine whether the recipients
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would become affected. Following blastocyst injec-
tion with MHV-A59 and embryo transfer, three from
ﬁve recipients littered 14 pups (Table 1). A total of
two from ﬁve and three from ﬁve recipients serocon-
verted by d14 and d21, respectively. With respect to
the pups, four from one litter were seropositive for
MHV on d42. By d63, only one pup was seropositive
and by d112 post embryo transfer it no longer had
detectable MHV antibodies. In the MMVp group, all
four recipients littered 14 pups. MMVp antibodies
were found neither in recipients nor in the pups.
When control blastocysts were injected with M2
medium, two out of two recipients littered nine pups.
During the experimental period, both recipients and
pups in the control group were seronegative for
MHV-A59 and MMVp. At d42, there was a signif-
icantly higher number of pups seropositive for MHV-
A59 (4/11) than for MMVp (0/11); P\0.05. PCR
analysis revealed that samples analyzed from all nine
pups were negative for MHV and/or MMV.
Experiment 2: culture of mESCs with MHV-A59
and MMVp
Pluripotency and viral status
The pluripotency and viral status, as measured by
FACS, were determined at P13 ? 5 ? 1 (data not
shown). The percentage of control mESCs positive
for POU5F1 alone, or positive for both POU5F1 and
MHV-A59, or positive for both POU5F1 and MMVp
was on average 80%, 3%, and 3%, respectively. For
cultures exposed to MHV-A59, the percentage of
cells positive for POU5F1 alone, or positive for both
POU5F1 and MHV-A59, or positive for MHV alone
was 55%, 32%, and 3%, respectively. For cultures
exposed to MMVp, the percentage of cells positive
for POU5F1 alone, or positive for both POU5F1 and
MMVp, or positive for MMV alone was 65%, 6%,
and 0%, respectively.
mESCs allow efﬁcient replication of MHV-A59
but not MMVp
From the four replications, the average number of
trypsinized cells in the control group was 3.1 9 10
6
at P13 ? 5 ? 1 and 3.2 9 10
6 at P13 ? 5 ? 4
(Fig. 1). Culture of mESCs with MMVp led to
1.4 9 10
6 cells at P13 ? 5 ? 1 and 2.1 9 10
6 at
P13 ? 5 ? 4. With respect to the cultures with
MHV-A59, 0.8 9 10
6 cells were found at
P13 ? 5 ? 1, and the number decreased to
1.4 9 10
4 cells at P13 ? 5 ? 4. The average viabil-
ity of the trypsinized control mESCs, MHV-A59- and
MMVp-exposed mESCs at P13 ? 5 ? 1 was 86%,
88%, and 89%, respectively. Signiﬁcant differences
were observed in the mean number of cells from
MMV cultures compared to MHV cultures at passage
P13 ? 5 ? 3 and in the mean cell numbers from the
control and MHV cultures in passage P13 ? 5 ? 4
(P\0.05).
At the ﬁrst two passages of culture 1 with MHV-
A59, the titer of the supernatant was higher than
10
10 TCID50/ml decreasing to 10
7.8 TCID50/ml at the
fourth passage (Table 2). At the ﬁrst passage of
Table 1 Results of blastocyst injection with MHV-A59 and MMVp suspensions and transfer into d2.5 pseudopregnant recipients
Virus Virus concentration
(TCID50/blastocyst)
Number
of litters/
Number of
recipients
Total number
of live pups (%)
Seropositive mice post embryo transfer
Recipients Progeny
d14 d21 d28 d42 d63 d42 d63
MHV-A59 10
0 3/5 14a
a 2/5a 3/5a 3/5a 3/5a 3/5a 4/11a
b 1/11a
c
MMVp 10
-5 4/4 14a
a 0/4a 0/4a 0/4a 0/4a 0/4a 0/11b 0/11a
Control M2 medium 2/2 9a
a 0/2a 0/2a 0/2a 0/2a 0/2a 0/6ab 0/6a
Different online alphabets within columns indicate signiﬁcant differences (P\0.05)
a Organs from three pups out of each group were investigated for the presence of MHV and/or MMV using PCR
b Pups originated from one litter
c Mice were seronegative between d84 and d112
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123culture 2, the titer of the supernatant was also higher
than 10
10 TCID50/ml decreasing to 10
7.5 TCID50/ml
at the fourth passage. With respect to MMVp, at the
ﬁrst passage of culture 1, the viral titer of the
supernatant was 10
4.8 TCID50/ml (Table 2). Viruses
were not detected at the third to the ﬁfth passage. At
the ﬁrst passage of culture 2, the viral titer of the
supernatant was 10
3.8 TCID50/ml decreasing to
10
1.3 TCID50/ml at the ﬁfth passage.
Blastocyst injection with mESCs exposed
to MHV-A59 and MMVp for 6 h resulted
in the production of chimeras
When mESCs were exposed to 10
4 TCID50 MHV-
A59/cell for 6 h and injected into blastocysts, one
from ﬁve recipients littered two non-chimeric pups
(Table 3). A total of four from ﬁve recipients
seroconverted by day 14 and showed the presence
of anti-MHV antibodies during the experimental
period. Both pups were seropositive for MHV on
d42 and, by d63, MHV antibodies were no longer
found. When mESCs were exposed to 10
-1 TCID50
MHV-A59/cell for 6 h and injected into blastocysts,
all ﬁve recipients littered 34 pups, 17 of which were
chimeric. Neither recipients nor pups were seropos-
itive for MHV-A59. In the MMVp group, when
mESCs were cultured with 10
-1 TCID50 MMVp/cell
for 6 h and injected into blastocysts, all ﬁve recip-
ients littered 30 pups, three of which were chimeric.
Neither recipients nor pups were seropositive for
MMVp. Control mESCs resulted in all three recip-
ients littering 16 pups, three of which were chimeric.
Control mice showed no anti-MHV-A59 and anti-
MMVp antibodies.
A signiﬁcantly higher number of chimeric pups
was born in the MHV-A59 group than in the MMVp
group where mESCs were inoculated with
10
-1 TCID50 MHV-A59 or MMVp/cell and in the
control group (P\0.05). Signiﬁcant differences
were observed in the number of seropositive recip-
ients in the MHV-A59 group (10
4 TCID50/cell)
compared to the MHV-A59 (10
-1 TCID50/cell) and
the MMV groups (P\0.05). With respect to the
progeny, a signiﬁcantly higher number of mice was
seropositive in the MHV-A59 group (10
4 TCID50/
cell) on d42 (P\0.05).
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Fig. 1 The average number
of cells found per replicate
(n = 4) after culture of
virus-exposed and control
mESCs over four passages.
mESCs were infected with
0.1 TCID50 MHV-A59 or
MMVp per cell; controls
were virus-free. The mESCs
were passaged every 2 days
Table 2 Viral titer of supernatants after culture of mESCs
with MHV-A59 or MMVp
Passage MHV-A59
(10
-1 TCID50/ES cell)
MMVp
(10
-1 TCID50/ES cell)
Culture 1 Culture 2 Culture 1 Culture 2
P13 ? 5 ? 1 [10
10 [10
10 10
4.8 10
3.8
P13 ? 5 ? 2 [10
10 10
8.3 10
3.8 10
3
P13 ? 5 ? 31 0
8.3 10
6.8 01 0
2
P13 ? 5 ? 41 0
7.8 10
7.5 01 0
1
P13 ? 5 ? 5 n.d. n.d. 0 10
1.3
n.d., not done
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to MHV-A59 and MMVp for 4 or 5 passages
did not result in the production of chimeras
When mESCs were exposed to 10
-1 TCID50 MHV-
A59/cell for four passages and injected into blasto-
cysts, ﬁve from 11 recipients littered 16 non-chimeric
pups (Table 4). A total of nine from 11 and 10 from
11 recipients seroconverted by d14 and d21, respec-
tively. All 16 pups were seropositive for MHV on
d42. By d63, six pups were seropositive and by d84
post embryo transfer no longer showed MHV anti-
bodies. When mESCs were cultured with
10
-1 TCID50 MMVp/cell for ﬁve passages and
injected into blastocysts, six from nine recipients
littered 22 non-chimeric pups. Neither recipients nor
pups were seropositive for MMVp throughout the
experimental period. Blastocyst injection with control
mESCs resulted in three from four recipients littering
19 pups, eight of which were chimeric. Control mice
showed no antibodies for MHV-A59 and MMVp.
A signiﬁcantly higher number of chimeric mice
was obtained in the control group (P\0.05). The
number of seropositive recipients and pups was
signiﬁcantly higher in the MHV-A59 group
(P\0.05).
Blastocyst injection with mESCs exposed
to MHV-A59 and MMVp for 6 h but not after
4 or 5 passages resulted in the production
of germline chimeras
Table 5 presents a summary of the reproductive and
serological data from the blastocyst injection with
mESCs exposed to the virus either for 6 h or four
(MHV-A59) or ﬁve (MMVp) passages. Following
6 h co-incubation of the mESCs with 10
4 and
10
-1 TCID50 MHV-A59/cell, from a total of 50
embryos, 1 and 5 litters from ﬁve recipients consisted
of 4% and 68% live pups, respectively, (P\0.05).
No germline chimeras were obtained from the group
receiving mESCs which were co-incubated with
Table 3 Results of blastocyst injection with MHV-A59- and MMVp-exposed (P13 ? 5 ? 6 h) mESCs and transfer into d2.5
pseudopregnant recipients
Virus Virus concentration
(TCID50/ES cell)
Number of litters/
Number of
recipients
Chimeric pups/
number of
live pups (%)
Seropositive mice days post embryo transfer
Recipients Progeny
d14 d21 d28 d42 d63 d42 d63
MHV-A59 10
4 1/5 0/2 (0)ab 4/5a 4/5a 4/5a 4/5a 4/5a 2/2a 0/2a
MHV-A59 10
-1 5/5 17/34 (50)b 0/5b 0/5b 0/5b 0/5b 0/5b 0/34b 0/34a
MMVp 10
-1 5/5 3/30 (10)a 0/5b 0/5b 0/5b 0/5b 0/5b 0/30b 0/30a
Control ESC medium 3/3 3/16 (19)a 0/3ab 0/3ab 0/3ab 0/3ab 0/3ab 0/16b 0/16a
Different online alphabets within columns indicate signiﬁcant differences (P\0.05)
Table 4 Results of blastocyst injection with MHV-A59 (P13 ? 5 ? 4) and MMVp (P13 ? 5 ? 5) exposed mESCs and transfer
into d2.5 pseudopregnant recipients
Virus Virus concentration
(TCID50/ES cell)
Number
of litters/
Number of
recipients
Chimeric pups/
number of
live pups
Seropositive mice days post embryo transfer
Recipients Progeny
d14 d21 d28 d42 d63 d42 d63
MHV-A59 10
-1 5/11 0/16a 9/11a 10/11a 10/11a 10/11a 10/11a 16/16a 6/16a
a
MMVp 10
-1 6/9 0/22a 0/9b 0/9b 0/9b 0/9b 0/9b 0/22b 0/22b
Control ESC medium 3/4 8
b/19b 0/4b 0/4b 0/4b 0/4b 0/4b 0/19b 0/19b
Different online alphabets within columns indicate signiﬁcant differences (P\0.05)
a All mice were seronegative by d84
b Three chimeras were females
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4 TCID50 MHV-A59/cell. In addition, one out of
ﬁve recipients from only this group was seropositive.
With respect to 6 h co-incubation of the mESCs with
10
-1 TCID50 MHV-A59/cell, 17 chimeras were born
to all ﬁve recipients that littered and eight chimeras
from three litters showed GLT. On average, seven
pups per germline chimera were born. One chimera
was female which did not give birth to pups. None of
the mice from this group had anti-MHV antibodies.
In the 10
-1 TCID50 MMVp/cell group, 60% of the
embryos resulted in live pups. From all recipients that
littered, three chimeras from two litters were
obtained, all of which showed GLT. An average of
6.7 pups per germline chimera was born. Mice in this
group were seronegative for MMV. In the control
group, 53% of the embryos resulted in live pups.
From the three recipients that littered, three chimeras
from two litters were obtained, all of which showed
GLT. An average of 6.7 pups per germline chimera
was born. Control mice were seronegative for MHV
and MMV.
Following culture of the mESCs with
10
-1 TCID50 MHV-A59 or MMVp/cell for four or
ﬁve passages, from a total of 110 and 120 embryos,
respectively, ﬁve out of 11 and six out of 12
recipients gave birth to litters with 16 and 22 pups,
respectively, (P[0.05). No chimeras were obtained
from these two groups. All ﬁve recipients from the
MHV-A59 group that littered were seropositive while
no anti-MMV antibodies were present in the recip-
ients from the MMV group. From the control
embryos, 48% resulted in live pups, the result being
signiﬁcantly different from that from both virus
groups (P\0.05). From the three recipients that
littered, eight chimeras were obtained, ﬁve of which
showed GLT. An average of 6.2 pups per germline
chimera was born. Mice were seronegative for both
MHV and MMV. Comparison of the MHV-A59
Table 5 Reproductive performance and serology of mice receiving blastocysts injected with MHV-A59 (P13 ? 5 ? 4) and MMVp
(P13 ? 5 ? 5) exposed mESCs
Parameter Period of culture and viral dose per mESC
P13 ? 5 ? 6 h P13 ? 5 ? 4/5
10
4 TCID50
MHV
10
-1 TCID50
MHV
10
-1 TCID50
MMV
Control ES
medium
10
-1 TCID50
MHV
10
-1 TCID50
MMV
Control ES
medium
Progeny/embryos
transferred (%)
2/50 (4)a 34/50 (68)b 30/50 (60)b 16/30 (53)b 16/110 (15)c 22/120 (18)c 19/40 (48)b
Litters/number of
transfers performed
1/5 5/5 5/5 3/3 5/11 6/12 3/4
Litters with chimeras
(number of mice)
0/1 (0) 5/5 (17)a
a 2/5 (3) 2/3 (3) 0/5 (0)b 0/6 (0) 3/4 (8)
b
Seropositive litters
(number of mice)
1/5 (2) 0/5(0)a 0/5(0) 0/3 (0) 5/5 (16)b 0/6 (0) 0/4 (0)
Seropositive litters with
chimeras (number
of mice)
0/1 (0) 0/5 (0) 0/5 (0) 0/3 (0) 0/5 (0) 0/6 (0) 0/4 (0)
Litters with germline
chimeras (number
of mice)
0/1 (0) 3/5 (8) 2/5 (3) 2/2 (3) 0/5 (0) 0/6 (0) 3/3 (8)
Germline chimeras/
chimeras
0/0 (0) 8/17 3/3 3/3 0/0 (0) 0/0 (0) 5/8
c
Germline progeny 0 56 20 20 0 0 31
Progeny/germline
chimera
0 7 6.7 6.7 0 0 6.2
Different online alphabets within rows indicate signiﬁcant differences (P\0.05)
a One non-germline female chimera was obtained
b Three female chimeras were obtained
c Two female germline chimeras were obtained
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-1 TCID50 MHV-A59/cell) after 6 h or
after four passages showed that there were signiﬁcant
differences in the number of litters with chimeras (5/5
vs. 0/5, respectively) and in the number of seropos-
itive litters (0/5 vs. 5/5, respectively) (P\0.05).
Discussion
The susceptibility of mESCs to infection with MHV-
A59 and MMVp and the risk of transmission of these
two viruses to mice by mESCs during blastocyst
injection and embryo transfer were investigated in the
present study. In addition, the effect of these viruses
on the GLT of the mESCs was determined. MHV and
MMV were chosen since they are among the most
prevalent viruses found in contemporary mouse
colonies and MHV replicates in the cytoplasm while
MMV replicates in the nucleus of the cell.
In a ﬁrst step, blastocysts were microinjected with
approximately 1 nl of the viral stocks to determine
whether the recipients would seroconvert and if the
reproductive efﬁciency would become affected. The
present data show that microinjection of blastocysts
with titers as high as 10
9 TCID50 MHV-A59/ml leads
to seroconversion of the recipients and, in some
cases, the pups also have anti-MHV antibodies,
which are of maternal origin. The titer of MMVp
used in this study did not lead to seroconversion of
the recipients and pups did not have anti-MMV
antibodies, implicating that the viral titer was too
low. Due to the small volume of liquid that was
injected indeed one blastocyst would have received a
maximum of 1 TCID50 MHV-A59 or 10
-5 TCID50
MMVp and recipients would have received a max-
imum dose of 10 TCID50 MHV-A59 or 10
-4 TCID50
MMVp since 10 blastocysts were transferred to each
recipient. In addition, the reproductive efﬁciency did
not appear to be affected by the presence of the
viruses, even with the high MHV dose, most likely
due to short-term exposure of the blastocysts to the
viruses and a lack of viral replication in the embryos
or fetuses themselves. All pups examined, including
those born to seropositive recipients, were free of the
virus, as shown by PCR analysis.
To our knowledge, there is only one report on the
microinjection of a murine virus into zygotes fol-
lowed by embryo transfer (Tebourbi et al. 2002).
After microinjection of the murine cytomegalovirus
(MCMV) into the cytoplasm of zygotes with a titer of
10
8 plaque-forming units (PFU)/ml, 10 washes with
M2 medium and embryo transfer, these workers
reported that the number of pups born per litter was
not affected by the presence of MCMV. Even though
PCR analysis detected MCMV DNA in in vitro
cultured embryos none was found in the pups and the
recipients (Tebourbi et al. 2002). In contrast, Baskar
et al. (1993) injected 5–20 molecules MCMV DNA
into the male pronucleus of each zygote with the
same technique that is used for transgenesis and
transferred the resulting blastocysts to recipients.
These workers reported smaller litter sizes, fetal
growth retardation, embryo resorption, abnormalities,
and MCMV DNA in fetal mice. In the present study,
pups from a MHV-seropositive mother showed the
presence of anti-MHV antibodies which decreased by
d112 post embryo transfer. Unfortunately, the amount
of MCMV microinjected (Tebourbi et al. 2002) and
the serological status of pups and recipients were not
reported. With respect to the reproductive perfor-
mance, the present results support the ﬁndings with
those using MCMV (Tebourbi et al. 2002).
In the present study, inoculation of the mESCs
with 0.1 TCID50/cell, culture, for 4–5 passages and
titration of the cell-free supernatants showed that a
productive infection was observed in the culture with
MHV-A59, whereas a restrictive infection was
observed in the culture with MMVp. This is sup-
ported by the ﬁnding that titers of the supernatants
from the cultures with MHV-A59 were over 10
7
TCID50/ml, whereas titers of the supernatants from
the cultures with MMVp decreased with time or there
was no detectable infectious virus present at later
passages. A total of eight mESC lines of different
genetic origin including B6, B6CBAF1 and 129/Sv,
which were inoculated with 0.1 multiplicity of
infection (moi), replicated MHV-2 and MHV-A59
over 2–3 days (Kyuwa 1997). The latter worker
observed titers of over 10
6 PFU/ml and little cyto-
pathic effect. In contrast to the study by Kyuwa
(1997), our results show that mESCs cultured with
MHV-A59 led to a well-pronounced cytolysis, lead-
ing to a decrease in cell numbers. In the study by
Kyuwa (1997), no information is available on the
number of cells cultured and/or infected by the two
MHV strains and culture was only short-term, in
contrast to the present study. A more-intensive in
vitro study, however, was performed by Okumura
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123et al. (1996) who demonstrated that 129/SvJ-derived
mESCs, which were inoculated with the less patho-
genic MHV-2 at a moi of 1, replicated the virus for
over 60 days, all cells were infected, viral titers
reached 10
6–10
9 PFU/ml and the pluripotency of the
mESCs was not affected.
Unlike the culture with MHV, in the present study,
no noticeable changes were observed with MMVp,
and cell numbers increased during culture. During
routine mESC culture, viral strains causing cytolysis
such as MHV-A59 would be detected morphologi-
cally while those that do not cause overt effects such
as MHV-2 (Okumura et al. 1996) could remain
undetected unless appropriate diagnostic methods
are employed.
Rodent parvoviruses bind to surface receptors
which are expressed on most cells and do not appear
to integrate into host chromosomes during either lytic
or persistent infections (Cornelis et al. 2004). Parvo-
virus replication in permissive cells within 20–30 h
(Ward and Tattersall 1982) leads to the release of
progeny virions and is usually associated with cell
death. In a restrictive host culture, the viral yield from
culture is always less than the multiplicity required to
obtain it. Even at a very high dose of 5–10 PFU/cell,
only 0.1–5% of cells are productively infected and
die (Ward and Tattersall 1982). The survivors
(95–99%) continue to grow and are not infectable
at the original multiplicity and therefore infections
dilute out rapidly. A previous study showed restric-
tive infection of murine embryonal carcinoma cells
(mECCs) with MMV (Miller et al. 1977). Less than
0.1% positive nuclei were detected when cells were
infected with 10 PFU/cell (Miller et al. 1977).
Blocking of replication of MMV in teratocarcinoma
stem cells is not total; a small fraction of infected
cells produce capsid antigen (Miller et al. 1977). In
the present study, 6% of the cells were found to be
positive for both POU5F1 and MMV at P13 ? 5 ? 1
by FACS analysis, thus supporting previous results
(Miller et al. 1977; Ward and Tattersall 1982). With
respect to replication of MMV, the mESCs used in
the present investigation are similar to mECCs.
Resistance to infection by MMV may involve the
transport of viral antigen or capsid to the nucleus
(Tattersall 1978) or as a result of post-adsorptional
events rather than of the lack of binding of virus to
the surface of the target cell (Spalholz and Tattersall
1983; Tattersall and Bratton 1983).
The present results show that blastocyst injection
with mESCs exposed to 10
-1 TCID50 MHV-A59 and
MMVp for 6 h resulted in the production of germline
chimeras. Furthermore, recipients were seropositive
for MHV-A59 but not for MMVp only when a high
dose of 10
4 TCID50/mESC was used. Pups were
seropositive for MHV-A59 when their mothers were
seropositive by day 14 post embryo transfer. Further-
more, this antibody was maternal in origin since it
decreased with time after birth. With respect to
germline chimera obtained, a similar number of
progeny was born when mESCs were virus-free or
cultured with 10
-1 TCID50 MHV-A59 or MMVp/cell
for 6 h. Culture with the higher dose (10
4 TCID50/
mESC) of MHV-A59 did not lead to the production of
chimeras. Similarly, culture with 10
-1 TCID50 MHV-
A59 or MMVp/cell over four or ﬁve passages did not
leadtotheproductionofchimeraswhereasthecontrols
were not affected. Furthermore, similar to the results
for the 6 h short-term culture with 10
4 TCID50 MHV-
A59/mESC, seroconversion also occurred with long-
term MHV-exposed (P13 ? 5 ? 4) but not MMV-
exposed (P13 ? 5 ? 5) mESCs. Blastocyst injection
with mESCs which were previously incubated for 1 h
with 1 PFU MCMV/cell led to the development of
normal offspring that contained no MCMV DNA
(Tebourbi et al. 2002). However, no data is available
on the antibody status of the recipients and pups from
that study. Similar to the present study where mESCs
were incubated with the viruses for 6 h, the lack of an
effect on the reproductive performance by co-incuba-
tion of mESCs with MCMV may be due to short-term
exposure.
The number of passages of mESCs could inﬂuence
the GLT. Nagy et al. (1993) reported that prolonged
in vitro culture affected the initial totipotency of the
R1 cell line (129/Sv 9 129/Sv-CP background),
whereas sublines were capable of further culture,
retaining their totipotency and giving rise to viable
chimeras. In the present study, mESCs were cultured
without feeder cells on gelatin to ensure reliable data
production from the mESCs alone. Due to the low
numbers of mESCs from cultures inoculated with
MHV-A59 at later passages it was not possible to
measure the pluripotency status using FACS. Instead,
the mESCs were used for blastocyst injections.
However, at P13 ? 5 ? 1, the percentage of mESCs
positive for POU5F1 alone was highest in the control
group (80%) compared to the MHV (55%) and MMV
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123groups (65%). The true test of pluripotency of
mESCs is the contribution to the germline. In this
study, the production of germline chimeras was
affected, indicating that the lack of GLT was due to
the presence of the viruses and not to the number of
passages since virus-free control mESCs led to
germline chimeras. The reason for a lack of GLT in
MHV-exposed mESCs may be attributed to effects
associated with cytolysis, perhaps due to inhibition of
the host macromolecular synthesis, but the mecha-
nism remains unclear as to why the GLT of MMV-
exposed mESCs was affected despite a restrictive
infection and a lack of anti-MMV antibodies in the
recipients and pups. The latter observation may be
due to changes in the nucleus of the mESCs since
MMV replicates in the nucleus of permissive cells but
this phenomenon warrants further study.
In conclusion, this study showed that viruses such
as MHV and MMV in mESC cultures inﬂuence the
GLT of the mESCs. In view of the increasing use of
mESCs in biomedical research, it is of paramount
importance to screen mESCs for unwanted microor-
ganisms prior to their use. In this way, early detection
could save valuable resources while misinterpreta-
tions of experimental results could be avoided. In
addition, use of pathogen-free mESCs is of impor-
tance to animal welfare since the number of mice
used for genetic engineering can be reduced.
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